Search

With a prevalence of 1/2500, long QT Syndrome (LQTS) is one of the leading causes of sudden cardiac death in young and otherwise healthy individuals. LQTS is a proarrhythmic disorder hallmarked by prolongation of cardiac repolarization due to underlying ion channelopathies. This translates to the typical electrocardiographic (ECG) findings of prolonged QT interval, notched or biphasic T waves, and T wave alternans, and puts individuals at high risk of developing ventricular tachyarrhythmias and sudden cardiac death. To date, there are 13 subtypes of LQTS classified according to the 13 identified genetic defects, all encoding subunits of cardiac ion channels (Kþ , Naþ , Ca2þ) or ion channel regulatory proteins. Current treatment options for LQTS including beta-blockers, left cardiac sympathetic denervation, and implantable cardioverter-defibrillators are largely palliative [1]. Each of these existing modalities is associated with limitations such as adverse effects related to drug and surgical therapies and the limited lifespan of implantable devices. In the age of molecular genetics, a molecular diagnosis of the underlying ion channel defect not only establishes the disease state but paves the way for personalized medicine. Recently, Lu et al. adopted the use of RNA interference technology to target and rescue the channelopathy phenotype observed in LQTS type 2 due to KCNH2 mutation [2]. RNA interference therapy is based on the concept derived from the natural cellular mechanism where sequence-specific gene silencing can be achieved by creation of double-stranded RNA [3]. A synthetic effector small

Over the last decade, there has been a surge in the implantations of devices for cardiac resynchronization therapy (CRT), with increasing recognition of their value in the management of medically refractory heart failure (HF). With this exponential growth, the need to offer the best quality of care after implantation has entailed an increase in healthcare spending. Frequent in-office follow-ups are limited by the immense healthcare cost, while emergency hospitalizations for acute decompensation of HF further contribute to the burden. Implantable sensors in the CRT device offer a unique opportunity for continuous monitoring of a patient's clinical HF status by measuring cardiac rhythm, intracardiac pressures, cardiac events, and physical activity, as well as detecting any device malfunction. Detecting early signs of a deteriorating clinical condition allows prompt preemptive medical intervention to optimize HF management. As a result, not only healthcare professionals will benefit from a reduction in hospitalizations and routine in-office follow-ups, but also patients will benefit from efficient management of their HF. This review highlights the latest available device-based remote monitoring systems and the most up-to-date evidence for the use of remote monitoring in CRT.